Does the media prefer TNDM or LIVN?

In the previous week, LivaNova had 1 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 3 mentions for LivaNova and 2 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.55 beat LivaNova's score of 0.58 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive LivaNova 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TNDM or IRTC?

In the previous week, iRhythm Technologies had 3 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 5 mentions for iRhythm Technologies and 2 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.55 beat iRhythm Technologies' score of 0.79 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive iRhythm Technologies 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MMED or TNDM?

MiniMed Group has higher revenue and earnings than Tandem Diabetes Care. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $2.99B 1.33 N/A N/A N/A Tandem Diabetes Care $1.03B 1.21 -$204.71M -$1.40 N/A

Does the media prefer MMED or TNDM?

In the previous week, MiniMed Group had 6 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for MiniMed Group and 2 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.55 beat MiniMed Group's score of 0.31 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tandem Diabetes Care 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Tandem Diabetes Care (TNDM) Competitors

$18.10 -0.50 (-2.69%)

As of 12:09 PM Eastern

Compare

TNDM vs. LIVN, IRTC, NVST, MMED, and SLNO

Should you buy Tandem Diabetes Care stock or one of its competitors? MarketBeat compares Tandem Diabetes Care with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tandem Diabetes Care include LivaNova (LIVN), iRhythm Technologies (IRTC), Envista (NVST), MiniMed Group (MMED), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.

How does Tandem Diabetes Care compare to LivaNova?

Tandem Diabetes Care (NASDAQ:TNDM) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Tandem Diabetes Care has higher earnings, but lower revenue than LivaNova. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.03B	1.21	-$204.71M	-$1.40	N/A
LivaNova	$1.39B	2.82	-$242.47M	$1.95	36.53

LivaNova has a net margin of 7.48% compared to Tandem Diabetes Care's net margin of -9.20%. LivaNova's return on equity of 16.48% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
LivaNova	7.48%	16.48%	7.59%

Tandem Diabetes Care presently has a consensus price target of $29.84, indicating a potential upside of 64.87%. LivaNova has a consensus price target of $79.38, indicating a potential upside of 11.42%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.57
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

97.6% of LivaNova shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tandem Diabetes Care has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, LivaNova had 1 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 3 mentions for LivaNova and 2 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.55 beat LivaNova's score of 0.58 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LivaNova beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to iRhythm Technologies?

Tandem Diabetes Care (NASDAQ:TNDM) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Tandem Diabetes Care has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

iRhythm Technologies has lower revenue, but higher earnings than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.03B	1.21	-$204.71M	-$1.40	N/A
iRhythm Technologies	$747.14M	4.49	-$44.55M	-$0.86	N/A

In the previous week, iRhythm Technologies had 3 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 5 mentions for iRhythm Technologies and 2 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.55 beat iRhythm Technologies' score of 0.79 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
iRhythm Technologies	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies has a net margin of -3.53% compared to Tandem Diabetes Care's net margin of -9.20%. iRhythm Technologies' return on equity of -10.26% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

Tandem Diabetes Care presently has a consensus price target of $29.84, indicating a potential upside of 64.87%. iRhythm Technologies has a consensus price target of $189.69, indicating a potential upside of 85.65%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.57
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

Summary

iRhythm Technologies beats Tandem Diabetes Care on 10 of the 14 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Envista?

Tandem Diabetes Care (NASDAQ:TNDM) and Envista (NYSE:NVST) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Tandem Diabetes Care has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, Envista has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Envista has a net margin of 2.41% compared to Tandem Diabetes Care's net margin of -9.20%. Envista's return on equity of 7.11% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Envista	2.41%	7.11%	3.91%

Envista has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.03B	1.21	-$204.71M	-$1.40	N/A
Envista	$2.72B	1.36	$47M	$0.41	55.63

Tandem Diabetes Care presently has a consensus target price of $29.84, suggesting a potential upside of 64.87%. Envista has a consensus target price of $28.83, suggesting a potential upside of 26.41%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, equities research analysts clearly believe Tandem Diabetes Care is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.57
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Tandem Diabetes Care had 2 more articles in the media than Envista. MarketBeat recorded 2 mentions for Tandem Diabetes Care and 0 mentions for Envista. Tandem Diabetes Care's average media sentiment score of 1.55 beat Envista's score of 1.00 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Overall Sentiment
Tandem Diabetes Care	Very Positive
Envista	Positive

Summary

Envista beats Tandem Diabetes Care on 8 of the 15 factors compared between the two stocks.

How does Tandem Diabetes Care compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

MiniMed Group has a net margin of 0.00% compared to Tandem Diabetes Care's net margin of -9.20%. MiniMed Group's return on equity of 0.00% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

MiniMed Group has higher revenue and earnings than Tandem Diabetes Care.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.33	N/A	N/A	N/A
Tandem Diabetes Care	$1.03B	1.21	-$204.71M	-$1.40	N/A

In the previous week, MiniMed Group had 6 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for MiniMed Group and 2 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.55 beat MiniMed Group's score of 0.31 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tandem Diabetes Care	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

19.7% of MiniMed Group shares are held by institutional investors. 2.2% of MiniMed Group shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MiniMed Group presently has a consensus target price of $21.67, indicating a potential upside of 53.34%. Tandem Diabetes Care has a consensus target price of $29.84, indicating a potential upside of 64.87%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Tandem Diabetes Care	1 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.57

Summary

MiniMed Group beats Tandem Diabetes Care on 10 of the 13 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Soleno Therapeutics has a net margin of 33.70% compared to Tandem Diabetes Care's net margin of -9.20%. Soleno Therapeutics' return on equity of 22.85% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

Soleno Therapeutics has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Tandem Diabetes Care	$1.03B	1.21	-$204.71M	-$1.40	N/A

97.4% of Soleno Therapeutics shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Tandem Diabetes Care had 1 more articles in the media than Soleno Therapeutics. MarketBeat recorded 2 mentions for Tandem Diabetes Care and 1 mentions for Soleno Therapeutics. Tandem Diabetes Care's average media sentiment score of 1.55 beat Soleno Therapeutics' score of 0.94 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Overall Sentiment
Soleno Therapeutics	Positive
Tandem Diabetes Care	Very Positive

Soleno Therapeutics currently has a consensus price target of $76.67, indicating a potential upside of 44.63%. Tandem Diabetes Care has a consensus price target of $29.84, indicating a potential upside of 64.87%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Tandem Diabetes Care	1 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.57

Soleno Therapeutics has a beta of -2.22, meaning that its share price is 322% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

Summary

Soleno Therapeutics beats Tandem Diabetes Care on 9 of the 17 factors compared between the two stocks.

Get Tandem Diabetes Care News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNDM vs. The Competition

Export

Metric	Tandem Diabetes Care	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.24B	$6.99B	$6.26B	$12.44B
Dividend Yield	N/A	1.21%	2.69%	5.30%
P/E Ratio	-12.93	44.80	22.35	24.23
Price / Sales	1.21	85.66	555.60	126.08
Price / Cash	N/A	24.40	42.31	57.88
Price / Book	7.90	7.06	9.82	6.73
Net Income	-$204.71M	$159.22M	$3.56B	$336.97M
7 Day Performance	22.13%	0.37%	-1.16%	0.79%
1 Month Performance	-7.09%	3.45%	3.85%	5.38%
1 Year Performance	-12.26%	0.47%	27.33%	34.55%

Tandem Diabetes Care Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNDM Tandem Diabetes Care	3.32 of 5 stars	$18.10 -2.7%	$29.84 +64.9%	-8.0%	$1.24B	$1.03B	N/A	2,500	Positive News Analyst Upgrade
LIVN LivaNova	2.9793 of 5 stars	$73.83 flat	$79.38 +7.5%	+68.9%	$4.06B	$1.39B	37.86	3,300
IRTC iRhythm Technologies	4.0368 of 5 stars	$116.56 flat	$191.85 +64.6%	-25.0%	$3.83B	$747.14M	N/A	2,400	Analyst Forecast
NVST Envista	3.4695 of 5 stars	$23.41 -0.1%	$28.83 +23.2%	+26.6%	$3.81B	$2.72B	57.09	12,000	Positive News
MMED MiniMed Group	3.738 of 5 stars	$11.87 flat	$21.67 +82.5%	N/A	$3.33B	$2.99B	N/A	8,000	News Coverage Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNDM) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. LIVN, IRTC, NVST, MMED, and SLNO

How does Tandem Diabetes Care compare to LivaNova?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Summary

How does Tandem Diabetes Care compare to Envista?

Summary

How does Tandem Diabetes Care compare to MiniMed Group?

Summary

How does Tandem Diabetes Care compare to Soleno Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. LIVN, IRTC, NVST, MMED, and SLNO

How does Tandem Diabetes Care compare to LivaNova?

Which has higher valuation & earnings, TNDM or LIVN?

Is TNDM or LIVN more profitable?

Do analysts recommend TNDM or LIVN?

Do insiders and institutionals believe in TNDM or LIVN?

Which has more volatility and risk, TNDM or LIVN?

Does the media prefer TNDM or LIVN?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Which has more volatility and risk, TNDM or IRTC?

Which has stronger valuation and earnings, TNDM or IRTC?

Does the media prefer TNDM or IRTC?

Is TNDM or IRTC more profitable?

Do analysts recommend TNDM or IRTC?

Summary

How does Tandem Diabetes Care compare to Envista?

Which has more volatility & risk, TNDM or NVST?

Is TNDM or NVST more profitable?

Which has better earnings & valuation, TNDM or NVST?

Do analysts rate TNDM or NVST?

Does the media favor TNDM or NVST?

Summary

How does Tandem Diabetes Care compare to MiniMed Group?

Is MMED or TNDM more profitable?

Which has stronger earnings and valuation, MMED or TNDM?

Does the media prefer MMED or TNDM?

Do institutionals and insiders have more ownership in MMED or TNDM?

Do analysts recommend MMED or TNDM?

Summary

How does Tandem Diabetes Care compare to Soleno Therapeutics?

Is SLNO or TNDM more profitable?

Which has better valuation and earnings, SLNO or TNDM?

Do institutionals & insiders have more ownership in SLNO or TNDM?

Does the media favor SLNO or TNDM?

Do analysts prefer SLNO or TNDM?

Which has more risk & volatility, SLNO or TNDM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools